Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
58 hedge funds and large institutions have $21.6M invested in Zynerba Pharmaceuticals, Inc in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 17 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
26% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $1.29M
20% more capital invested
Capital invested by funds: $18.1M → $21.6M (+$3.55M)
12% less funds holding
Funds holding: 66 → 58 (-8)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$3.51M |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$976K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$921K |
| 4 |
Renaissance Technologies
New York
|
+$476K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$451K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
-$1.29M |
| 2 |
Millennium Management
New York
|
-$652K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$374K |
| 4 |
Walleye Capital
New York
|
-$171K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$154K |
ZYNE Hedge Fund Activity: Q4 2020 in Review
58 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2020, worth a combined $21.6M — up 20% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ZYNE and 9 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 20 added.
The largest buyer was ETF Managers Group, adding an estimated $3.51M. The largest seller was Prentice Capital Management, exiting entirely with an estimated $1.29M sold.
- 58 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2020, down from 66 in Q3 2020.
- Funds reported $21.6M of Zynerba Pharmaceuticals, Inc stock for Q4 2020, up 20% quarter-over-quarter.
- 9 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2020 and 17 closed out, a net change of -8 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2020 was ETF Managers Group, an estimated $3.51M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2020 was Prentice Capital Management, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2020.